Loading stock data…
MAZE
$23.32-0.61 (-2.55%)
Market OpenUpdated 3:02 PM EDT
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Maze Therapeutics, Inc. in the Healthcare sector is trading at $23.32 with a market capitalization of $1.4B. Wall Street consensus targets $62.55 (11 analysts), implying a +168.2% move over the next 12 months. The stock is currently 57% below its 52-week high of $53.65, remaining 30.4% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: MACD remains below its signal line. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +168.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $20.00M | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$26.55M↑ | -$38.06M↓ | -$32.97M↑ | -$36.47M↓ | -$35.40M |
| Net Income | -$24.21M↑ | -$34.57M↓ | -$30.09M↑ | -$33.68M↓ | -$32.79M |
Peer Comparison
JNJUNHPFE
Fundamentals
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibit...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.38B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-35.86%
Volume
Today's trading volume
438,862
Recent News
Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right Now
Maze Therapeutics Inc. (NASDAQ:MAZE) is one of the oversold stocks to buy right now. On May 12, Maze Therapeutics highlighted in their corporate and financial update positive topline data from the Phase 2 HORIZON trial of MZE829. The trial evaluated the oral inhibitor in patients with APOL1-mediated kidney disease/AMKD. The results provided clinical proof-of-concept, showing […]
Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?
This clinical-stage biotech advancing precision medicines reported a notable insider sale amid strong one-year share performance.
Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares
Maze Therapeutics is a U.S. biotech advancing clinical-stage precision medicines for renal and metabolic diseases.
Industry Analysts Just Made A Stunning Upgrade To Their Maze Therapeutics, Inc. (NASDAQ:MAZE) Revenue Forecasts
Maze Therapeutics, Inc. ( NASDAQ:MAZE ) shareholders will have a reason to smile today, with the analysts making...
Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates
Maze Therapeutics, Inc. (MAZE) delivered earnings and revenue surprises of -5.07% and +23.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?